SCHEMBL4224014

SCHEMBL4224014

Cc1cccc(NC(=O)N(CCCN(C)C)Cc2ccc(C(=O)Nc3ccccc3N)nc2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 12/20 0.49
HDAC3 O15379 10/20 0.49
HDAC2 Q92769 7/20 0.49
HDAC10 Q969S8 3/20 0.43
KMT2A Q03164 2/20 0.43
MITF O75030 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC8 Q9BY41 4/20 0.43
PDCD1 Q15116 3/20 0.42
CD274 Q9NZQ7 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
NCOR2 Q9Y618 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 2/20 0.40
HDAC11 Q96DB2 1/20 0.40
NCOR1 O75376 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382347 0.95 HDAC3 (0.48) HDAC1HDAC3HDAC2HDAC10KMT2A
SCHEMBL13569886 0.92 HDAC3 (0.47) HDAC1HDAC3HDAC2HDAC10KMT2A
SCHEMBL4225104 0.92 MITF (0.47) HDAC1HDAC3HDAC2HDAC10KMT2A
SCHEMBL4224159 0.91 HDAC1 (0.46) HDAC1HDAC3HDAC2HDAC10HDAC8
SCHEMBL2384379 0.91 ROCK2 (0.47) HDAC1HDAC3HDAC2HDAC10SMN1; SMN2
SCHEMBL1497083 0.90 KMT2A (0.42) HDAC1HDAC3HDAC2KMT2AMITF
SCHEMBL4224075 0.89 HDAC1 (0.45) HDAC1HDAC3HDAC2HDAC10KMT2A
SCHEMBL4222700 0.89 HDAC1 (0.46) HDAC1HDAC3HDAC2HDAC10SMN1; SMN2
SCHEMBL2385437 0.88 HDAC1 (0.49) HDAC1HDAC3HDAC2HDAC10HDAC8
SCHEMBL4229735 0.88 HDAC1 (0.46) HDAC1HDAC3HDAC2HDAC10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012972-B2 Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-06 US disclosed
US-8012972-B2 Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-06 US disclosed
US-20100063045-A1 NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-11 US disclosed
US-20100063045-A1 NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-11 US disclosed
US-20100056522-A1 INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-04 US disclosed
US-20100056522-A1 INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-04 US disclosed
EP-2133339-A1 NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063045-A1 NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE HCAR1, CBR1, UACA HDAC1 1000/4885HDAC3 1018/4885HDAC2 1438/4885
US-20100056522-A1 INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT HDAC1, HDAC9, HDAC5 HDAC1 1/4885HDAC3 9/4885HDAC2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.